Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 295
- Registration Number
- NCT04468984
- Locations
- πΊπΈ
Hospital of the University of Pennsylvania /ID# 219001, Philadelphia, Pennsylvania, United States
π¨π¦Princess Margaret Cancer Centre /ID# 253942, Toronto, Ontario, Canada
π¦πΉKlinikum Wels-Grieskirchen GmbH /ID# 220915, Wels, Oberoesterreich, Austria
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
- Conditions
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 84
- Registration Number
- NCT04455841
- Locations
- πΊπΈ
Start Midwest, Grand Rapids, Michigan, United States
πΊπΈEmory University-Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 21
- Registration Number
- NCT04454658
- Locations
- π¦πΊ
Royal Perth Hospital /ID# 241678, Perth, Western Australia, Australia
πΊπΈThe Mount Sinai Hospital /ID# 221549, New York, New York, United States
πΊπΈUniversity of Oklahoma, Stephenson Cancer Center /ID# 224095, Oklahoma City, Oklahoma, United States
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2020-06-25
- Target Recruit Count
- 100
- Registration Number
- NCT04446806
- Locations
- π¨π³
First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CyclophosphamideDrug: FludarabineDrug: MelphalanDrug: MethotrexateDrug: Mycophenolate MofetilDrug: RuxolitinibDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Bone Marrow Aspiration and BiopsyProcedure: Magnetic Resonance ImagingProcedure: Ultrasound Imaging
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT04384692
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 211
- Registration Number
- NCT04377620
- Locations
- πΊπΈ
Temple University, Philadelphia, Pennsylvania, United States
πΊπΈWenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
πΊπΈNorthshore University Health System, Chicago, Illinois, United States
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Prisma Health-Upstate
- Target Recruit Count
- 20
- Registration Number
- NCT04374149
- Locations
- πΊπΈ
Prisma Health, Greenville, South Carolina, United States
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT04362137
- Locations
- π¬π§
Novartis Investigative Site, Manchester, United Kingdom
Ruxolitinib to Combat COVID-19
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT04354714
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
- Conditions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04355793
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.